Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 2548 results for methods

  1. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

  2. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  3. Colli-Pee for first void urine collection (MIB273)

    NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .

  4. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

  5. Blogs

    assessment Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real...

  6. Glaucoma: diagnosis and management (NG81)

    This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open-angle glaucoma and ocular hypertension and on effective diagnosis, treatment and reassessment to stop these conditions progressing.

  7. Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessment

    In development Reference number: GID-HTE10057 Expected publication date:  22 January 2026

  8. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

  9. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)

    This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.

  10. About our guidance

    Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

  11. Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

    Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.

  12. LiMAx system for assessing the functional capacity of the liver (MIB168)

    NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .

  13. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

  14. Transperineal template biopsy and mapping of the prostate (IPG364)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  15. Laparoscopic retroperitoneal lymph node dissection for testicular cancer (IPG158)

    Evidence-based recommendations on laparoscopic retroperitoneal lymph node dissection for testicular cancer. This involves using smaller openings in the skin (keyhole surgery) to remove the lymph nodes.